Skip to Content

Join the 'Methotrexate' group to help and get support from people like you.

Methotrexate News

Fewer Childhood Cancer Survivors Dying From 'Late' Effects

Posted 13 Jan 2016 by Drugs.com

WEDNESDAY, Jan. 13, 2016 – Fewer childhood cancer survivors are dying years later from lingering effects of the treatment that conquered their cancer, a new study finds. Experts called the report, published in the Jan. 14 issue of the New England Journal of Medicine, "very good news." "The findings substantiate what experts in the field have hoped would be true," said lead researcher Dr. Gregory Armstrong, of St. Jude Children's Research Hospital, in Memphis, Tenn. Survival rates from many childhood cancers are high, but survivors still face what doctors call "late effects" – health problems that develop months to years after the cancer treatment has ended. Among U.S. children who survived cancer back in the 1970s and '80s, 18 percent died within the next 25 years, Armstrong said. Sometimes, the initial cancer comes back. Often though, the health issues are related to the very ... Read more

Related support groups: Cancer, Methotrexate, Fluorouracil, Xeloda, Hydroxyurea, Mercaptopurine, Hydrea, Carboplatin, Cisplatin, Dacogen, Temodar, Cytoxan, Cyclophosphamide, Oxaliplatin, Treanda, Bendamustine, Gemzar, Gemcitabine, Capecitabine, Hodgkin's Lymphoma

Childhood Cancer Treatment May Raise Adult Heart Disease Risk

Posted 5 Jan 2016 by Drugs.com

MONDAY, Jan. 4, 2016 – Children who survive cancer may face a higher risk of heart disease as adults, new research suggests. The lingering effects of the treatments that saved their lives as children may trigger the development of heart abnormalities that might not cause apparent symptoms, the researchers explained. The investigators found that heart disease appears to affect between 3 percent and 24 percent of pediatric cancer survivors by the time they reach their 30s. Those figures rose to between 10 and 37 percent among patients 40 and older, the study found. However, while the study revealed a link between childhood cancer treatment and later heart disease, it didn't prove cause-and-effect. "The prevalence of these cardiac findings might be expected in an older adult population, but not necessarily in this young a population," said study lead author Dr. Daniel Mulrooney. ... Read more

Related support groups: Cancer, Heart Disease, Methotrexate, Fluorouracil, Cardiac Arrhythmia, Xeloda, Cardiomyopathy, Hydroxyurea, Left Ventricular Dysfunction, Mercaptopurine, Hydrea, Carboplatin, Cisplatin, Temodar, Cytoxan, Dacogen, Cyclophosphamide, Gemzar, Treanda, Bendamustine

Girls Given Risky Meds Don't Get Contraceptive Advice

Posted 16 Dec 2015 by Drugs.com

WEDNESDAY, Dec. 16, 2015 – New research from a Midwestern hospital suggests a wide majority of teen girls and young women fail to get information about contraceptives when they take medications that could cause birth defects. At issue are so-called "teratogenic" medications, used for conditions ranging from acne to anxiety, that boost the risk of birth defects when taken during pregnancy. Physicians often tell sexually active women to take birth control while they're on the drugs to avoid becoming pregnant, but it's unclear whether younger females routinely get the same kind of guidance. In the new study, researchers examined the medical records of nearly 1,700 females aged 14 to 25 who received just over 4,500 prescriptions for teratogenic medications in more than 4,100 visits from 2008-2012. All the participants had visited a large, unidentified pediatric medical center in the ... Read more

Related support groups: Birth Control, Xanax, Contraception, Plan B, Klonopin, Emergency Contraception, Mirena, Sprintec, Clonazepam, NuvaRing, Implanon, Provera, Ativan, Valium, Nexplanon, Depo-Provera, Ortho Tri-Cyclen, Tri-Sprintec, Topamax, Yasmin

Kidney Woes Tied to Raised Cancer Risk, Study Finds

Posted 12 Nov 2015 by Drugs.com

THURSDAY, Nov. 12, 2015 – Kidney failure and having a kidney transplant may increase the risk for certain types of cancer, a new study suggests. Poor kidney function and immune system-suppressing drugs may be behind this increased risk, according to Elizabeth Yanik, of the U.S. National Cancer Institute, and colleagues. For the study, published in the Nov. 12 online edition of the Journal of the American Society of Nephrology, the researchers looked at data from more than 200,000 U.S. kidney transplant candidates and recipients. Along with finding that these patients are at increased risk for certain types of cancer, the investigators also identified clear patterns of risk associated with different types of treatment. However, the associations seen in the study do not prove cause-and-effect. The risk of kidney and thyroid cancers was especially high when kidney failure patients were on ... Read more

Related support groups: Cancer, Methotrexate, Renal Failure, CellCept, Gilenya, Tysabri, Imuran, Chronic Kidney Disease, Orencia, Xolair, Revlimid, Leflunomide, Azathioprine, Arava, Afinitor, Tecfidera, Peritoneal dialysis, Mycophenolate Mofetil, Myfortic, Aubagio

Worse Psoriasis, Less Healthy Arteries, Study Finds

Posted 8 Oct 2015 by Drugs.com

THURSDAY, Oct. 8, 2015 – The skin disorder psoriasis appears linked with artery inflammation, raising the odds for heart disease, a new study says. "As the amount of psoriasis increases, the amount of blood vessel inflammation increases," said senior investigator Dr. Nehal Mehta, a clinical investigator with the U.S. National Heart, Lung, and Blood Institute. His team also found that even mild psoriasis may indicate an increased risk for heart attack and stroke. Just one psoriasis skin patch, or plaque, "might be biologically active, causing low-grade inflammation and starting a cascade, speeding up their blood vessel disease," Mehta said. "People really should know that psoriasis is not just a cosmetic disease," he added. However, these study findings only show an association between psoriasis and blood vessel inflammation, not a direct cause-and-effect relationship, Mehta said. His ... Read more

Related support groups: Methotrexate, Psoriasis, Inflammatory Conditions, Plaque Psoriasis, Coronary Artery Disease (CAD), Soriatane, Dovonex, Acute Coronary Syndrome, Tazorac, Oxsoralen, Taclonex, Acitretin, Calcipotriene, Tazarotene, Resorcinol, Acute Coronary Syndrome - Prophylaxis, Anthralin, Vectical, Dritho-Scalp, Psoriatec

U.S. Oncologists Decry High Cost of Cancer Drugs

Posted 23 Jul 2015 by Drugs.com

THURSDAY, July 23, 2015 – Soaring costs for cancer drugs are hurting patient care in the United States, a group of top oncologists claim. "High cancer-drug prices are affecting the care of patients with cancer and our health care system," Dr. Ayalew Tefferi, a hematologist at Mayo Clinic in Rochester, Minn., said in a Mayo news release. Tefferi and his colleagues made a number of recommendations on how to address the problem in a commentary published July 23 in the Mayo Clinic Proceedings. Allowing Medicare to negotiate drug prices is one of the suggestions the team of 118 leading cancer experts offered as a possible solution. Along with their recommendations, the group also expressed support for a patient-based grassroots movement on change.org that is demanding action on the issue. "The average gross household income in the U.S. is about $52,000 per year. For an insured patient with ... Read more

Related support groups: Cancer, Provera, Depo-Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Prostate Cancer, Tamoxifen, Medroxyprogesterone, Arimidex, Tretinoin, Femara, Fluorouracil, Lupron Depot, Gleevec, Lung Cancer, Rituxan, Colorectal Cancer, Renal Cell Carcinoma

Gene Discoveries Could Help Rheumatoid Arthritis Treatment

Posted 28 Apr 2015 by Drugs.com

TUESDAY, April 28, 2015 – Genetic variations may hold clues to rheumatoid arthritis – suggesting not only who will develop the painful condition, but also predicting its severity and even who might die from it, a new study says. "Genetic factors predisposing to disease, to disease severity, and response to treatment will allow tailoring treatment to individual patients' needs," said lead researcher Dr. Sebastien Viatte, a research fellow at the University of Manchester in England. Using data from several sources on thousands of patients in the United Kingdom, researchers found that gene mutations at a location on a chromosome called HLA-DRBl were associated with rheumatoid arthritis severity and the response to treatment with tumor necrosis factor (TNF) inhibitor drugs. This study, Viatte said, is a potentially important first step toward personalized medicine for patients with the ... Read more

Related support groups: Rheumatoid Arthritis, Methotrexate, Humira, Enbrel, Remicade, Plaquenil, Hydroxychloroquine, Rituxan, Imuran, Otezla, Orencia, Rituximab, Cimzia, Leflunomide, Juvenile Rheumatoid Arthritis, Azathioprine, Arava, Simponi, Xeljanz, Infliximab

FDA Medwatch Alert: Injectable Products by Mylan: Recall - Presence of Particulate Matter

Posted 25 Apr 2015 by Drugs.com

including certain lots of: Gemcitabine for Injection Carboplatin Injection Methotrexate Injection Cytarabine Injection See the press release for a listing of the product strength, NDC, and lot numbers affected by this recall. Some products may be packaged with a Pfizer Injectables label (see Background below)   [Posted 04/24/2015] ISSUE: Mylan N.V. is conducting a voluntary nationwide recall to the hospital/user level of select lots of injectable products due to the presence of visible foreign particulate matter observed during testing of retention samples. Administration of a sterile injectable that has foreign particulates has the potential of severe health consequences. Intrathecal administration could result in a life threatening adverse event or result in permanent impairment of a body function. Intravenous administration has the potential to damage and/or obstruct blood ... Read more

Related support groups: Cancer, Methotrexate, Carboplatin, Gemzar, Gemcitabine, Cytarabine, Cytosar, Methotrexate LPF Sodium, Trexall, Cytosar-U, Paraplatin, Otrexup, Tarabine PFS, Folex PFS, Rheumatrex Dose Pack, Carboplatin Novaplus, Rasuvo

Some Arthritis Meds Cost Seniors Thousands Annually

Posted 21 Apr 2015 by Drugs.com

TUESDAY, April 21, 2015 – Arthritis medications known as biologic disease-modifying drugs can cost Medicare patients more than $2,700 in co-payments a year, a new report finds. Researchers say the tab is an immense burden on patients with disabling conditions such as rheumatoid arthritis, a chronic disorder that affects an estimated 1.3 million Americans. Biologic anti-rheumatic medications – which include drugs such as adalimumab (Humira), anakinra (Kineret) and etanercept (Enbrel) – have allowed patients to gain better control of rheumatoid arthritis when taken early in the course of disease, the researchers explained. But some of the new drugs top $20,000 annually, according to the April 21 online report in the journal Arthritis & Rheumatology. "Many patients face a growing and unacceptable financial burden for access to treatment," said study lead author Dr. Jinoos Yazdany of the ... Read more

Related support groups: Rheumatoid Arthritis, Methotrexate, Humira, Enbrel, Remicade, Plaquenil, Hydroxychloroquine, Rituxan, Imuran, Orencia, Otezla, Rituximab, Leflunomide, Azathioprine, Arava, Xeljanz, Infliximab, Etanercept, Adalimumab, Penicillamine

Lower Doses of Rheumatoid Arthritis Drugs May Work for Some

Posted 5 Nov 2014 by Drugs.com

WEDNESDAY, Nov. 5, 2014 – Some people in the early stages of rheumatoid arthritis may be able to safely lower their medication doses once their symptoms are well under control, a new study suggests. In a clinical trial, British researchers found that many patients were able to remain in remission for months after their doctors lowered their doses of the drugs methotrexate and Enbrel (etanercept). What's more, some continued to do well when they were taken off the drugs altogether, the researchers said in the Nov. 6 issue of the New England Journal of Medicine. The findings suggest it's "reasonable" to lower, or even stop, certain patients' medication doses, wrote the researchers, led by Dr. Paul Emery of the University of Leeds. But experts not involved in the study stressed that there are some big unknowns. For one, it's not clear which patients would likely do well if their drug ... Read more

Related support groups: Rheumatoid Arthritis, Methotrexate, Enbrel, Etanercept, Trexall, Methotrexate LPF Sodium, Otrexup, Folex PFS, Rheumatrex Dose Pack, Rasuvo

Medicines Are Biggest Culprit in Fatal Allergic Reactions: Study

Posted 10 Oct 2014 by Drugs.com

THURSDAY, Oct. 9, 2014 – Although food allergies have garnered a lot of attention lately, a new study reports that medications are actually the biggest cause of sudden deaths related to allergy. Over a little more than a decade, nearly 60 percent of the allergy-related deaths were caused by medications, while less than 7 percent were caused by food allergies, the study found. "Medications can be dangerous," said study researcher Dr. Elina Jerschow, director of the Drug Allergy Center at Montefiore Medical Center and assistant professor of medicine at Albert Einstein College of Medicine, in New York City. While research from other countries has reported medications as a major culprit in anaphylaxis-related deaths, Jerschow said, the problem has been less defined in the United States. One reason is that there is no national registry for anaphylaxis deaths, she said. The study was ... Read more

Related support groups: Provera, Amoxicillin, Depo-Provera, Doxycycline, Metronidazole, Clindamycin, Cephalexin, Penicillin, Methotrexate, Bactrim, Azithromycin, Cipro, Ciprofloxacin, Accutane, Augmentin, Levaquin, Lupron, Flagyl, Keflex, Zithromax

FDA Approves Rasuvo (methotrexate) Injection

Posted 14 Jul 2014 by Drugs.com

Chicago, IL, July 14, 2014 – Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced that the U.S. Food and Drug Administration (FDA) has approved Rasuvo, a subcutaneous injectable methotrexate (MTX) therapy delivered in an auto-injector for rheumatoid arthritis (RA), polyarticular-course juvenile idiopathic arthritis (pJIA) and psoriasis. Rasuvo will be available in 10 dosage strengths, ranging from 7.5 mg to 30 mg in 2.5 mg increments and will be launched in the U.S. The company concurrently announced that the U.S. District Court for the District of Delaware has denied a motion for a preliminary injunction filed by Antares Pharma, Inc. “We’re delighted to have secured approval for our lead product, Rasuvo, and look forward to introducing this much-needed therapy to the ma ... Read more

Related support groups: Rheumatoid Arthritis, Methotrexate, Psoriasis, Juvenile Idiopathic Arthritis

Otrexup (Methotrexate) Injection Approved By FDA

Posted 15 Oct 2013 by Drugs.com

EWING, N.J., October 14, 2013 — Antares Pharma, Inc. today announced the approval of Otrexup (methotrexate) injection by the U.S. Food and Drug Administration (FDA). Otrexup is the first FDA approved subcutaneous (SC) methotrexate (MTX) for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. Otrexup is indicated for adults with severe active rheumatoid arthritis (RA) who have had an insufficient therapeutic response to or are intolerant of an adequate trial of first line therapy including full dose non-steroidal anti-inflammatory agents (NSAIDs), or children with active polyarticular juvenile idiopathic arthritis (pJIA). The FDA also approved adult use of Otrexup for symptomatic control of severe recalcitrant, disabling psoriasis that is not adequately responsive to other forms of therapy. In 2012, approximately six million prescriptions were w ... Read more

Related support groups: Rheumatoid Arthritis, Methotrexate, Psoriasis, Juvenile Rheumatoid Arthritis, Juvenile Idiopathic Arthritis

Kidney Damage a Risk of Some Childhood Cancer Treatments, Finds Study

Posted 24 Sep 2013 by Drugs.com

TUESDAY, Sept. 24 – Some adult survivors of childhood cancer are at increased risk for kidney problems, a new study says. The study included more than 1,100 adults, aged 18 and older, who were followed for five to 42 years after being diagnosed and treated for childhood cancer. The researchers examined the long-term effects of kidney-damaging treatments, including the chemotherapy drugs ifosfamide, cisplatin, carboplatin, high-dose methotrexate and high-dose cyclophosphamide; radiation therapy to the kidney region; and partial or complete surgical removal of the kidney (nephrectomy). Compared with patients who did not receive kidney-damaging treatments, those who were treated with ifosfamide or cisplatin and those who underwent nephrectomy had poorer kidney function, which persisted throughout the follow-up period. The researchers also found that patients treated with high doses of ... Read more

Related support groups: Cancer, Methotrexate, Renal Failure, Carboplatin, Cisplatin, Cytoxan, Cyclophosphamide, Platinol, Trexall, Methotrexate LPF Sodium, Ifex, Neosar, Platinol-AQ, Folex PFS, Paraplatin, Carboplatin Novaplus, Ifosfamide, Rheumatrex Dose Pack, Cytoxan Lyophilized

Expensive or Not, Rheumatoid Arthritis Drugs Have Similar Effect: Study

Posted 1 Jul 2013 by Drugs.com

MONDAY, July 1 – Treatment with a pricey biological drug was no better than cheaper, conventional therapy in terms of reducing time off from work for people with rheumatoid arthritis, a new study finds. Swedish researchers assessed lost work days among rheumatoid arthritis patients who had not responded to initial treatment with a standard medication, methotrexate. The group of 204 patients were randomly given either the biological drug infliximab (Remicade) or conventional combination therapy with the non-biologics sulfasalazine plus hydroxychloroquine. At the start of the study, the average amount of lost work time was 17 days per month for all patients. During the 21-month study, the patients receiving conventional therapy lost about six fewer days of work per month, compared with about five fewer days for those taking Remicade – not a significant difference. Regardless of the ... Read more

Related support groups: Rheumatoid Arthritis, Methotrexate, Remicade, Plaquenil, Hydroxychloroquine, Sulfasalazine, Infliximab, Azulfidine, Sulfazine, Trexall, Methotrexate LPF Sodium, Quineprox, Rheumatrex Dose Pack, Azulfidine EN-tabs, Plaquenil Sulfate, Folex PFS

Page 1 2 Next

Ask a Question

Further Information

Related Condition Support Groups

Rheumatoid Arthritis, Psoriatic Arthritis, Ectopic Pregnancy, Dermatomyositis, Psoriasis, Brain Tumor, Acute Lymphoblastic Leukemia, Uveitis, Eczema, view more... Pancreatic Cancer, Systemic Sclerosis, Scleroderma, Mycosis Fungoides, Head and Neck Cancer, Breast Cancer, Pityriasis rubra pilaris, Neoplastic Diseases, Non-Hodgkin's Lymphoma, Pemphigus, Soft Tissue Sarcoma, Acute Lymphocytic Leukemia, Acute Nonlymphocytic Leukemia, Bullous Pemphigoid, Trophoblastic Disease, Esophageal Carcinoma, Choriocarcinoma, Cogan's Syndrome, Cervical Cancer, Hodgkin's Lymphoma, Juvenile Idiopathic Arthritis, Colorectal Cancer, Solid Tumors, Small Cell Lung Cancer, Mantle Cell Lymphoma, Graft-versus-host disease, Gastric Cancer, Bladder Cancer, Lymphoma, Meningeal Leukemia, Ovarian Cancer, Osteosarcoma, Non-Small Cell Lung Cancer, Pemphigoid

Related Drug Support Groups

Trexall, Methotrexate LPF Sodium, Rasuvo, Otrexup, Rheumatrex Dose Pack, Folex PFS

Methotrexate Patient Information at Drugs.com